From Molecule to Clinical Outcome. Every Step.
Mechanistic drug effect simulation that runs the full biological chain — pharmacogenomics, pharmacokinetics, pharmacodynamics, pathways, disease progression, biomarkers, toxicity — in sequence, on the patient in front of you.
One Chain, Not Many Tools
A PK software package gives you concentration curves. A pathway analysis tool tells you which genes are affected. Neither connects the biology all the way through to what a clinician would actually measure in a trial. Most drug effect prediction tools model one layer and stop — leaving the rest to interpretation, assumption, or a separate vendor.
OVIVO connects the full chain. From a patient's genetic makeup through drug absorption, metabolism, receptor engagement, pathway modulation, and disease progression — translated into the clinical endpoints that trials actually measure. Each module passes typed, structured outputs directly into the next. Every value carries a provenance record: what data source it came from, what confidence was assigned, what calculation produced it.
The Module Chain
Seven mechanistic modules, chained end-to-end from patient genetics to clinical outcome. Each module conditions the next — the output of PGx shapes PK, which shapes PD, which drives pathway modulation, and so on through to benefit-risk.
Pharmacogenomics
Star allele calling from the patient's genome. Metabolizer phenotype classification across CYP2D6, CYP2C19, CYP2C9, and other pharmacogenes — with continuous activity scores, not binary bins. Sources: PharmVar, CPIC, DPWG, PharmGKB.
Pharmacokinetics
Concentration-time profiles for every drug in the regimen, adjusted for the patient's renal and hepatic function, age, weight, albumin, and CYP enzyme activity. Formulation-specific absorption kinetics, drug-drug interaction quantification, and population PK variability.
Pharmacodynamics
Target engagement and receptor occupancy over time. Emax modeling, hysteresis handling, therapeutic window assessment, and combination pharmacology — including synergy and antagonism quantification.
Pathway Modulation
Drug-target engagement propagated through biological networks using Reactome, KEGG, and WikiPathways — with disease-stage weighting. The same drug in an early-stage patient produces a different pathway response than in a late-stage patient.
Disease & Biomarkers
Stage-aware disease progression modeling against calibrated natural history baselines — treatment effect expressed relative to what would have happened without it. Mechanism-driven biomarker predictions: HbA1c, LDL-C, eGFR, NT-proBNP, MMSE, CDR-SB, and others.
Toxicity & Benefit-Risk
Organ-specific risk scoring across hepatic, cardiac, renal, neurological, and hematological dimensions. Off-target pharmacology profiling, hERG liability, ADR likelihood estimates. Integrated benefit-risk summary with patient-specific modifiers propagated through the full chain.
Every number OVIVO produces has a chain of custody. The data source. The confidence level. The calculation method. The system will fail explicitly rather than substitute invented parameters — if a required value cannot be found, the module reports the gap. It does not fill it with fabrication.
Patient-Level, Not Population-Average
Most simulation tools model the average patient. OVIVO does not have an average patient. The same drug can produce dramatically different outcomes in different people — not as a statistical observation, but as a mechanistic prediction.
A patient with CYP2D6 poor metabolizer status, stage 3 chronic kidney disease, and an active statin regimen is not the average patient. Their PK is different. Their DDI profile is different. Their pathway response is different. Their simulation reflects all of it.
Population-level results emerge from the distribution of individual-level predictions — not from aggregate assumptions applied downward.
Authoritative Data Sources
The platform maintains a shared knowledge database populated on-demand from authoritative external sources. Every retrieved value is stored with its provenance and made available to all downstream modules.
Co-Development
For Pharma, Biotech, and CRO partners looking to apply the simulation chain to pipeline de-risking, safety prediction, DDI characterization, or combination regimen design.
develop@ovivolabs.comInvestments
A mechanistically grounded simulation platform with a validated accuracy record and a growing library of reconstructed trials. Clear trajectory from research tool to industry infrastructure.
invest@ovivolabs.comMedia & Research
Press inquiries, academic collaboration, and general research questions about the platform's methodology, data sources, and validation approach.
media@ovivolabs.com